Embecta (EMBC) EBITDA Margin (2020 - 2026)

Embecta (EMBC) posted EBITDA Margin of 15.78% for Q1 2026, down 50.52% sequentially from 31.89% in Q4 2025, and down 851.0% YoY from 2.1% in Q1 2025.

Embecta (EMBC) EBITDA Margin (2020 - 2026) Analysis & Trends

Embecta has reported EBITDA Margin for 7 years, with the latest figure at 15.78% in Q1 2026.

Quarterly EBITDA Margin fell 851.0% year-over-year to 15.78% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 25.78% (up 969.0% YoY) and the FY2025 annual result came in at 22.41%, up 756.0% from the prior year.
EBITDA Margin slipped to 15.78% in Q1 2026 per EMBC's latest filing, from 31.89% in the prior quarter.
Over five years, EBITDA Margin peaked at 36.03% in Q1 2022 and troughed at 1.09% in Q3 2022.
A 5-year average of 20.21% and a median of 20.06% in 2023 frame the typical range for EBITDA Margin.
The sharpest annual moves came in 2022 and 2025: EBITDA Margin sank 4006 bps in 2022, then jumped 2093 bps in 2025.
Over 5 years, EBITDA Margin stood at 32.21% in 2022, then slumped by 49 bps to 16.41% in 2023, then slumped by 33 bps to 10.96% in 2024, then soared by 191 bps to 31.89% in 2025, then slumped by 51 bps to 15.78% in 2026.
According to Business Quant data, EBITDA Margin over the past three periods registered 15.78%, 31.89%, and 21.4% for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Intuitive Surgical	132.71 Bn	127.50 Bn	1.96 Bn	33.60%
2	Becton Dickinson	51.57 Bn	50.71 Bn	2.32 Bn	13.31%
3	Alcon	35.52 Bn	34.17 Bn	1.68 Bn	0.39%
4	Resmed	33.28 Bn	31.81 Bn	861.22 Mn	30.66%
5	Medline	27.86 Bn	25.18 Bn	2.22 Bn	5.14%
6	West Pharmaceutical Services	25.15 Bn	24.71 Bn	329.20 Mn	20.53%
7	Solventum	15.31 Bn	14.91 Bn	1.29 Bn	8.19%
8	Cooper Companies	14.86 Bn	14.72 Bn	735.40 Mn	-2.87%
9	Baxter International	13.63 Bn	11.48 Bn	1.03 Bn	7.33%
10	Embecta	319.59 Mn	101.39 Mn	153.30 Mn	17.92%

Download Data